The commensal bacterium Akkermansia muciniphila has garnered considerable attention for its association with leanness as well as for its other health benefits in relation to obesity, excess weight and type 2 diabetes.

The gut microbiota is now believed to be a factor involved in the onset of cardiometabolic disorders such as obesity. In human and rat studies, the commensal* bacterium Akkermansia muciniphila– which is naturally present in large quantities in the gut microbiota of healthy people – has been gaining a lot of attention for its association with leanness and for producing several health benefits against obesity and type 2 diabetes.

Scientists struggle to understand why some gut bacteria are sensitive to antibiotics while a fraction of them survive treatment. New research in mice reveals that gut microbial metabolism alongside diet play a key role in modifying the extent of gut microbiome disruption in response to antibiotics.

Crohn’s Disease (CD) is one of the sets of inflammatory bowel disease (IBD) that consists of chronic inflammation of the terminal ileum, that can extend throughout the gastrointestinal tract. Researchers have focused more on the role the gut microbiota plays in CD over the years to better understand disease progression. Increased endotoxemia, inflammation, fungal loads and changes in the gut microbiota composition, as well as altered mucins production have been observed in CD patients compared to healthy populations.